|
||||||||||||||||||||||
|
|
Phase II Chemotherapy with Yoshi 864 for Chronic Myelocytic Leukemia
Basic Trial Information
Objectives I. Assess the effectiveness of Yoshi 864 in chronic myelocytic leukemia. Entry Criteria Disease Characteristics: See General Eligibility Criteria Patient Characteristics: See General Eligibility Criteria General Eligibility Criteria: Patients with chronic myelocytic leukemia which has not progressed to advanced phases. Patients must have 30,000 or more wbc, a life expectancy of 6 weeks or more, and may have the PH1 chromosome without concomitant splenomegaly or leukocyte alkaline phosphatase above 30 pluses. Expected Enrollment Protocol closed 05/76. Outline Nonrandomized study. Single-agent Chemotherapy. Yoshi 864, Yoshi, NSC-102627. Trial Lead Organizations Central Oncology Group
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |